Abstract

Simple SummaryThe outcome of hepatocellular carcinoma (HCC) patient varies depending on tumor burden and liver function. The BCLC staging system is based on these two factors while AJCC staging system is based on tumor burden only. However, the outcome of HCC does not solely depend on these two factors, but also the aggressiveness of tumor behavior represented by tumor morphology. The morphology of HCC can be divided into three types; nodular, multinodular confluent and infiltrative type. The infiltrative type is known to be associated with poor prognosis and should be staged differently from other tumors. This study revealed that large infiltrative type HCC (≥4 cm) was associated with worse survival especially in early AJCC T-stages (T1b/2) and BCLC stages (A/B). In addition, reassignment of large infiltrative tumor to T3 and T4 and to BCLC B and C increased the discriminatory ability of each staging system.Infiltrative gross morphology of hepatocellular carcinoma (HCC) is known to be associated with poor prognosis, but this is not considered for staging. A total of 774 HCC patients who underwent curative liver resection were retrospectively reviewed and the prognostic significance of infiltrative type HCC was assessed using the American Joint Committee on Cancer (AJCC) and Barcelona Clinic Liver Cancer (BCLC) staging systems. Seventy-four patients (9.6%) had infiltrative HCCs with a higher proportion of multifocal tumors, larger tumors, vessel invasion, increased tumor marker levels, and advanced T-stages than those with nodular HCC (all, p < 0.01). Infiltrative morphology was independently associated with lower overall survival (OS), but its impact was significant when the tumor size was ≥ 4 cm (p < 0.001). Under current AJCC and BCLC staging criteria, these large infiltrative HCCs were associated with significantly worse OS in early AJCC T-stages (T1b/T2, p < 0.001) and BCLC stage A/B (both, p < 0.01) but not in late AJCC (T3/T4) and BCLC C. The reassignment of this subtype to T3 and T4 increased the discriminatory ability of AJCC T-staging with lower AIC values (3090 and 3088 vs. 3109) and higher c-index (0.69 and 0.69 vs. 0.67), respectively (both, p < 0.001). Similarly, the reassignment of large infiltrative HCC to BCLC stages B and C also improved the prognostic performance. Large infiltrative HCCs should be assigned to more advanced stages in current staging systems for their prognostic impact.

Highlights

  • Hepatocellular carcinoma (HCC) is the sixth most common cancer and is the second most lethal cancer type globally [1,2]

  • 40.3% of the patients were older than 60 years, 78.4% were male, and 77.6% were infected with the hepatitis B virus (HBV)

  • 74 (9.6%) showed the gross morphology of the infiltrative type hepatocellular carcinoma (HCC), while on imaging findings, infiltrative type was observed in 69 patients

Read more

Summary

Introduction

Hepatocellular carcinoma (HCC) is the sixth most common cancer and is the second most lethal cancer type globally [1,2]. Despite the overall poor prognostic nature of HCC, the patient outcome varies depending on the tumor burden and liver function in each patient [3]. The American Joint Committee on Cancer (AJCC) system for HCC is a standard tumor staging system dealing with tumor burden, defined by the size, number, and vessel invasion of tumors in the liver, and their nodal and systemic metastasis. The AJCC staging system was developed and validated using patients who underwent liver resection [4,5]. The unique role of liver function when assessing the prognosis of HCC patients led to the development of the so-called “clinical staging systems for HCC,” which incorporates the markers of liver function as well as the tumor extent. The Barcelona Clinic Liver Cancer (BCLC) staging system is a well-known clinical staging scheme for HCC patients that properly stratifies patients according to prognosis, simultaneously linking up with treatment indication [6]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call